Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | KRAS | P01116 | 7/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 3/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | FABP3 | P05413 | 1/20 | 0.39 |
| ▸ | FABP2 | P12104 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25338022 | 0.89 | HTR7 (0.44) | NTSR1FPR2HTR7HDAC6 | |
| SCHEMBL21810428 | 0.85 | NTSR1 (0.57) | NTSR1HTR2AHTR2CKRASATM | |
| SCHEMBL13836584 | 0.84 | NTSR1 (0.51) | NTSR1ATMROCK2HDAC6 | |
| SCHEMBL5069199 | 0.83 | PLA2G4A (0.55) | ATMROCK2HDAC6 | |
| SCHEMBL4485443 | 0.82 | NTSR1 (0.52) | NTSR1HTR2AHTR2CKRASATM | |
| SCHEMBL19470070 | 0.82 | PLA2G4A (0.43) | ATMROCK2HDAC6 | |
| SCHEMBL20676201 | 0.81 | KRAS (0.47) | NTSR1HTR2AHTR2CKRASHTR7 | |
| SCHEMBL27844158 | 0.81 | NPY5R (0.45) | ATMROCK2HDAC6 | |
| SCHEMBL3597779 | 0.80 | KMT2A (0.59) | NTSR1HTR2AHTR2C | |
| SCHEMBL30229742 | 0.80 | KMT2A (0.59) | NTSR1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | BET1, BRD4, PHKB | NTSR1 4591/4885HTR2A 4152/4885HTR2C 4522/4885 |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | BET1, BRD4, PHKB | NTSR1 4587/4885HTR2A 4156/4885HTR2C 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.